Shenzhen Weiguang Biological Products Co (SZSE:002880) Total Liabilities : ¥941 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Shenzhen Weiguang Biological Products Co Total Liabilities?

Shenzhen Weiguang Biological Products Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥941 Mil.

Shenzhen Weiguang Biological Products Co's quarterly Total Liabilities increased from Sep. 2023 (¥691.95 Mil) to Dec. 2023 (¥831.14 Mil) and increased from Dec. 2023 (¥831.14 Mil) to Mar. 2024 (¥940.83 Mil).

Shenzhen Weiguang Biological Products Co's annual Total Liabilities increased from Dec. 2021 (¥215.23 Mil) to Dec. 2022 (¥708.20 Mil) and increased from Dec. 2022 (¥708.20 Mil) to Dec. 2023 (¥831.14 Mil).

Shenzhen Weiguang Biological Products Co Total Liabilities Historical Data

The historical data trend for Shenzhen Weiguang Biological Products Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Weiguang Biological Products Co Total Liabilities Chart

Shenzhen Weiguang Biological Products Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

136.64

231.24

215.23

708.20

831.14

Shenzhen Weiguang Biological Products Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															743.12	688.18	691.95	831.14	940.83

Shenzhen Weiguang Biological Products Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shenzhen Weiguang Biological Products Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	265.989	+	(499.787	+	65.364
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	831

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2876.779	-	2045.639
	=	831

Shenzhen Weiguang Biological Products Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	328.854	+	(546.342	+	65.634
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	941

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3033.262	-	2092.433
	=	941

Shenzhen Weiguang Biological Products Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shenzhen Weiguang Biological Products Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Weiguang Biological Products Co (SZSE:002880) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Weiguang Biological Products Co Ltd (SZSE:002880) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Guangming Street, No. 3402, Guangqiao Avenue, Guangming New District, Guangdong Province, Guangming, CHN, 518107

Website

http://www.szwg.com

Shenzhen Weiguang Biological Products Co Ltd is the pharmaceutical company. It is mainly engaged in the research and development, production and sales of blood products. The company's products portfolio includes human albumin, intravenous immunoglobulin (pH4), lyophilized human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus Human immunoglobulin, histamine human immunoglobulin, human fibrinogen, a total of 21 varieties of 21 specifications.

Executives

Guo Cai Ping

Executives

Shenzhen Weiguang Biological Products Co (SZSE:002880) Headlines

No Headlines